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Introduction
Breast cancer is the most frequently diagnosed cancer in women and the second leading cause of cancer-related from 98% in localized disease to 80% with regional spreading to only 26% with metastatic disease. Chemotherapy plays an important role in breast cancer, whether in the neoadjuvant, adjuvant, or metastatic setting. Single chemotherapeutic agents included in the National Comprehensive Cancer Network (NCCN) listing of preferred single agents are anthracyclines (e.g., doxorubicin, epirubicin, pegylated liposomal doxorubicin), taxanes (e.g., paclitaxel, docetaxel), vinorelbine, and capecitabine, each of which may be used as a single agent for recurrent or metastatic disease [2] . Among the taxanes, for example, single-agent paclitaxel has been shown to be active in first-line (chemotherapynaïve) patients with metastatic disease, yielding response rates of 25%-34% [3] [4] [5] , while docetaxel has shown activity in previously treated (second-line) metastatic settings, with response rates of 33%-43% [6] [7] [8] . Bolus 5-fluorouracil (5-FU) infusions, with leucovorin, have been shown to have substantive activity, yielding response rates of 36% in chemotherapy-naïve patients [9] and 17%-23% in patients with prior chemotherapy [10] [11] [12] . Continuous infusion 5-FU with leucovorin has yielded response rates of around 29% [13] . However, the encouraging results associated with continuous infusion therapy for the treatment of breast cancer are accompanied by inconvenience and cost in patient quality of life (QoL) and medical resources.
Capecitabine (Xeloda ® ; Hoffmann-La Roche Inc., Nutley, NJ) is a novel, orally administered fluoropyrimidine carbamate used to treat breast and colorectal cancer. Readily absorbed by the gastrointestinal tract, capecitabine is metabolized by the enzyme carboxylesterase in the liver, where it is converted to 5ʹdeoxy-5-fluorocytidine (5ʹDFCR), which is then converted by the enzyme cytidine deaminase to 5ʹdeoxy-5-fluorouridine (5ʹDFUR) [14, 15] . In tumor and normal tissues, the enzyme thymidine phosphorylase (TP) converts 5ʹDFUR to 5-FU. However, unlike parenterally administered 5-FU, oral capecitabine concentrates predominantly in tumor tissue as opposed to adjacent healthy tissue and plasma [15] . As a result, orally administered capecitabine enables physicians treating breast cancer to mimic the effect of continuous infusion 5-FU but in a convenient outpatient setting without the complications and costs associated with infusion pumps and parenteral therapies [16, 17] . Capecitabine was approved in 1998 by the U.S. Food and Drug Administration as a single agent for patients with metastatic breast cancer that is resistant to both paclitaxel and anthracyclines, and for those with breast cancer resistant to paclitaxel and for whom further anthracycline therapy is contraindicated [18] . Capecitabine is also approved for combination therapy with docetaxel for the treatment of patients with metastatic breast cancer in whom prior anthracycline-based therapy has failed. Standard dosing is 1,250 mg/m 2 orally twice daily (bid), morning and evening, for 14 consecutive days in 3-week cycles. There has, however, been substantial research into the utility of single-agent capecitabine in both earlier stages of breast cancer and at lower doses than the standard dose. This paper summarizes the efficacy, safety, QoL effects, and pharmacoeconomics of single-agent capecitabine for the treatment of metastatic breast cancer.
Methodology
MEDLINE was searched for published clinical studies, and proceedings from the American Society of Clinical Oncology (ASCO), the San Antonio Breast Cancer Symposium (SABCS), the European Society for Medical Oncology (ESMO), and the European Cancer Conference (ECCO) were searched for abstracts pertaining to capecitabine as a single agent for the treatment of breast cancer. The most recent available efficacy, safety, and QoL data were used when possible. Missing data were designated as "not available" unless one could infer results from other supplied data. Measures of variance were employed where possible to provide a perspective of uncertainty for comparing data across studies with varying sample sizes. Where variance data for proportions were not provided in the study, 95% confidence intervals (95% CIs) were calculated using the proportion method [19] . If inferential statistics for comparisons of proportions within randomized controlled studies were not provided by the study authors, the Fisher's exact test was employed to calculate these. Significance was set at 5% (α = .05) with two-tailed testing.
Metastatic Disease: First-Line
Based on promising findings in patients previously treated for metastatic disease, single-agent oral capecitabine is being investigated for treating earlier treatment settings of breast cancer. One area of particular interest is the first-line treatment of elderly patients with metastatic disease.
In a key randomized controlled trial (RCT) among elderly patients, O'Shaughnessy et al. [20] treated women ≥55 years of age with 3-week cycles of either oral capecitabine, 1,255 mg/m 2 bid for 2 weeks on/1 week off (n = 61), or cyclophosphamide with methotrexate and 5-FU (CMF) (n = 32). Although not statistically significant, activity appeared greater in the single-agent capecitabine group than in the CMF group (objective response rate [ORR], 30% vs. 16%; p = .21), as were median time to progression (MTTP) (4.1 vs. 3.0 months) and median overall survival (MOS) (19.6 vs. 17.2 months). The incidence of all-grade diarrhea (47% vs. 22%; p = 0.02) and hand-foot syndrome (HFS) (43% vs. 0%; p <.0001) were significantly greater with capecitabine than with CMF; the incidence In an open-label study, Minea et al. [21] treated 63 elderly patients (median age, 70 years; range, 65-78 years), none of whom had undergone prior chemotherapy for metastatic disease, with first-line oral standard-regimen capecitabine. The therapy was active, yielding an ORR of 27% (95% CI, 17%-40%) and stable disease (SD) rate of 43% (95% CI, 31%-56%). There were no treatmentrelated deaths, and the most common grade 3 or grade 4 AEs included asthenia, 13% (95% CI, 6%-24%); diarrhea, 10% (95% CI, 4%-20%); vomiting, 6% (95% CI, 2%-16%); and mucositis, 3% (95% CI, 1%-12%), with grade 2 or 3 HFS in 24% (95% CI, 14%-36%) of patients. More recently, Bajetta et al. [22] treated 73 patients ≥65 years of age (93% chemotherapy-naïve for metastatic disease) with single-agent capecitabine. The first 30 patients received the standard dose and regimen, but because of two (7%) deaths, both a result of severe dehydration, the investigators decided to reduce the initial capecitabine dose to 1,000 mg/m 2 bid for the next 43 patients (low-dose cohort). Activity was substantive and similar in both cohorts (lowdose cohort: complete response [CR] rate, 2%; ORR, 35%; SD rate, 46%; standard cohort: CR rate, 3%; ORR, 37%; SD rate, 33%). The MTTP were also similar (4.1 vs. 3.9 months), but the low-dose cohort appeared to have a greater median survival (16 vs. 10 months). The low-dose cohort also appeared to benefit from a more favorable safety profile than the standard-dose cohort, as demonstrated by lower incidences of grade 3 or 4 diarrhea (2% vs. 13%), dyspnea (5% vs. 10%), nausea (5% vs. 7%), and vomiting (0% vs. 3%). Grade 3 HFS was uncommon (2%). Only grade 3 or 4 fatigue appeared substantially more commonly in the lowdose cohort (12% vs. 7%). There was, however, one death resulting from heart failure, possibly associated with the study medication. These findings appear to show that single-agent capecitabine, particularly at the 1,000 mg/m 2 bid dosage, is an effective first-line therapy for elderly patients with metastatic breast cancer.
Metastatic Disease: Second-line (or Later)
Most studies of single-agent capecitabine for the treatment of metastatic breast cancer have been primarily among patients previously treated with an anthracycline (e.g., doxorubicin, epirubicin) and/or a taxane (e.g., docetaxel, paclitaxel). Such patients have a very poor prognosis, as exemplified in a recent study in which anthracycline-and taxane-resistant patients, following salvage chemotherapy with 48-hour continuous infusion 5-FU (biomodulated with high-dose leucovorin and in combination with cyclophosphamide), had overall 1-and 2-year survival rates of only 51% and 20%, respectively, and 0% after 28 months [23] .
Efficacy
Response and survival data for previously treated (second-line or later) metastatic therapy with single-agent capecitabine are presented in Table 1 [47, 48] . Down-dosing of capecitabine was reported in fewer than half of the studies, but this proportion may be greater because of reporting deficiencies in abstracts. Where reported, capecitabine was often reduced to approximately 75% of the initial dose for approximately one quarter to one half of the patients in the studies.
Overall, single-agent capecitabine was active in these poor-prognosis populations. Among these studies, the median CR rate was 3% (range, 0%-20%), and the median ORR was 28% (range, 9%-53%). Among prospective studies with at least 100 patients, the median CR rate was 2% (range, 0%-4%), the median ORR was 20% (range, 9%-35%), and the median SD rate was 43% (range, 35%-47%). Among all reported studies, the MTTP for these poor-prognosis patients was 4.7 months (range, 2.8-11.8 months), and the MOS was 11.0 months (range, 5.3-18.1 months). Among prospective studies with at least 100 patients, the MTTP was 3.5 months (range, 3.0-5.9 months) and the MOS was 11.9 months (range, 10.1-15.2 months).
Single-agent capecitabine has also been shown to exhibit at least comparable activity with that of singleagent paclitaxel in patients previously treated with an anthracycline and/or 5-FU. In one randomized phase II clinical trial [42] , 22 patients received oral capecitabine at a dose of 1,255 mg/m 2 bid for 2 weeks on/1 week off for two cycles, and 19 patients received parenteral paclitaxel at a dose of 175 mg/m 2 every 3 weeks. The CR rate and ORR were greater in the capecitabine group than in the paclitaxel group (14% vs. 0% and 36% vs. 26%, respectively), but these differences were not significant (p = .24 and p = .52). Survival data, as measured by MTTP for the capecitabine and paclitaxel groups (3.0 vs. 3.1 months) and MOS (7.6 vs. 9.4 months), were similar.
In a recent retrospective analysis of 197 patients previously treated with an anthracycline, taxane, and/or vinorelbine (French compassionate-use program) [27] , multivariate analyses showed that a favorable response to capecitabine therapy was associated with longer survival (relative risk [RR], 5.2; 95% CI, 2.0-13.6; p = .001). Another retrospective study that included 113 anthracycline-and taxane-refractory patients [52] reported that those treated with single-agent capecitabine had a significantly longer MOS time than those treated with single-agent vinorelbine (6.2 vs. 3.4 months; p < .0001).
Identifying patients who are most likely to respond to capecitabine therapy may substantially improve upon these findings. The HER-2/neu (also known as c-erbB-2) oncogene encodes a transmembrane tyrosine kinase receptor that is homologous to the epidermal growth factor receptor [53] . Amplification of the HER-2/neu gene, or overexpression of the HER-2 (p185 HER2 ) protein, has been associated with a poor prognosis in breast cancer [53] . Sezgin et al. [32] treated 58 heavily pretreated metastatic breast cancer patients (97% of whom had prior anthracycline-and taxane-based therapy either in the adjuvant or metastatic settings; 72% of whom had at least three prior regimens) with capecitabine at a dose of 1,000 mg/m 2 bid for 2 weeks on/ 1 week off to identify potential predictors of progressionfree survival. Patients with HER-2/neu ≥2+, as measured by immunohistochemistry, had a significantly shorter progression-free survival time than patients with HER2/neu expression of 0 or 1+ (3.7 vs. 7.4 months; p = .012) and a nearly significant lower ORR (10% vs. 32%; p = .073). The authors concluded that capecitabine had substantial antitumor activity in patients whose tumor does not overexpress the HER-2 receptor.
Safety
Single-agent capecitabine was well tolerated in patients previously treated with anthracyclines or taxanes for metastatic breast cancer. Dose reductions of single-agent capecitabine were frequently reported among patients receiving an initial dose of the labeled 1,250 mg/m 2 bid (days 1-14 every 3 weeks) [24, 28-30, 34, 40, 42, 45, 46, 50] . Such dose reductions were typically 25% and were observed in 12%-50% of patients in studies reporting dose reductions. However, only one study [26] reported dose reductions when lower initial doses were used.
Grade 3 or 4 AEs for patients previously treated with anthracyclines or taxanes are presented in Table 2 [24-35, 37, 40-48, 50, 51, 54, 55] . Overall, the most frequently reported grade 3 or 4 nonhematologic AEs were HFS (median, 13%; range, 0%-42%), diarrhea (median, 7.5%; range, 0%-30%), nausea (median, 6.5%; range, 0%-35%), mucositis (median, 6%; range, 0%-12%), and vomiting (median, 4%; range, 0%-19%). Grade 3 or 4 paresthesia or neuropathy was reported in only one study (27% and 4%, respectively) [46] . Hematologic grade 3 or 4 AEs were uncommon in studies, as observed by a median neutropenia incidence of 1% and median rates of 0% for thrombocytopenia, leukopenia, and lymphocytopenia.
A phase II RCT by Talbot et al. [42] compared the safety profile of single-agent capecitabine with that of singleagent paclitaxel in patients who had failed or were resistant to anthracycline-based therapy and/or who had undergone 19 (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) All regimens used twice daily dosing, 2 weeks on/1 week off, unless otherwise noted.
Wist et al. [29] : HFS includes grade 2; nausea includes grade 2. Lee et al. [24] www.TheOncologist.com prior 5-FU therapy. The overall incidence of grade 3 AEs was lower but not statistically significant for those treated with single-agent capecitabine than for those treated with single-agent paclitaxel (36% vs. 68%; p = .06). Although there were no significant differences between the groups in the incidence of grade 3 or 4 nonhematologic AEs, patients treated with capecitabine had significantly fewer shifts from baseline to grade 3 or 4 neutropenia (9% vs. 53%; p = .005). Grade 3 neutropenia was also significant less with capecitabine than with paclitaxel (0% vs. 26%; p = .016), as was grade 3 leukopenia (0% vs. 21%; p = .038).
In addition, HFS, commonly observed among patients treated with capecitabine, may be dosage-related. Among the 197 patients in the French compassionate-use program [27] , 20% treated with greater than 1,250 mg/m 2 bid capecitabine experienced severe HFS, compared with only 2% initially treated with lower-dose capecitabine.
Elderly Patients
In general, physicians need to monitor elderly patients being treated with capecitabine for potential adverse effects [18] . Recent studies by Longo et al. [31] and Zamora et al. [28] have shown that single-agent capecitabine is safe and active for the treatment of elderly patients with metastatic breast cancer who were previously treated with chemotherapy. Although there were no CRs, 20%-28% of elderly patients in those studies exhibited a partial response to single-agent capecitabine, and another 44%-50% exhibited SD, similar to the ORRs and SD rates observed overall in studies of single-agent capecitabine for second-line metastatic breast cancer. Dose reduction was needed for patients treated with capecitabine at a dose of 1,250 mg/m 2 bid [28] but not for those treated with 1,000 mg/m 2 bid [31] . The incidence of grade 3 HFS was greater with 1,250 mg/m 2 bid dosing than with 1,000 mg/m 2 dosing (18% vs. 7%), as was the incidence of grade 3 or 4 mucositis (12% vs. 7%). There were no reported cases of grade 3 or 4 diarrhea or hematologic toxicities with either dose level.
Of note, with particular relevance to the elderly, the package insert prepared for U.S. distribution contains cautionary recommendations when prescribing doses of capecitabine for patients with moderate to severe renal dysfunction or for those receiving warfarin therapy.
Quality of Life
Single-agent oral capecitabine has been shown to significantly improve QoL in patients previously treated for metastatic breast cancer. In a small study, Jakob et al. [43] reported that half of the 12 patients treated with the standard oral capecitabine regimen had improved QoL scores, as measured by the European Organization for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ). A more recent study by Fumoleau et al. [30] , who used the same regimen and questionnaire on 119 anthracycline-and taxane-resistant patients, reported significant improvements in mean Global Health Status from baseline (10 points) after 6 and 12 treatment cycles.
There have been several reports from a large, ongoing Brazilian study of QoL [56] [57] [58] [59] . Most recently, 611 anthracycline-and/or taxane-resistant patients with metastatic breast cancer received the standard regimen of oral capecitabine and were evaluated at baseline, week 7, week 13, and at end of treatment using the EORTC QLQ and BR-38 questionnaires [56, 60, 61] . Improvement in QoL was defined as an increase ≥10 points, and worsening QoL was defined by a decrease ≥10 points from baseline at one or more visits. Treatment with oral capecitabine led to significant improvements in patient global health status (p < .0001), physical functioning (p = .049), role functioning (p < .0001), emotional functioning (p < .0001), social functioning (p = .015), body image (p < .0001), sexual enjoyment (p = .015), financial problems (p = .002), and future perspectives (p < .0001). Patients treated with capecitabine also reported significant improvements in systemic therapy side effects (p < .0001) as well as in fatigue (p = .003), nausea and/or vomiting (p < .0001), pain (p < 0.0001), insomnia (p < .0001), appetite loss (p < .0001), constipation (p < .0001), diarrhea (p = .005), alopecia (p < .0001), breast symptoms (p < .0001), and arm symptoms (p = .0085). Approximately 70%-80% of patients reported improved or maintained QoL during treatment with capecitabine, with statistically significant improvements at each visit.
Cost-Effectiveness
Compared with other therapies for second-line (or later) metastatic breast cancer, single-agent oral capecitabine appears to be cost-effective. In a retrospective cohort study [62] matched by treatment, the medical and retail pharmacy claims of 100 patients with metastatic breast cancer treated with single-agent capecitabine were compared with those of 100 patients treated using other therapies, including vinorelbine, gemcitabine, cyclophosphamide, doxorubicin (with or without cyclophosphamide), and trastuzumab. Oral capecitabine provided superior cost-effectiveness compared with other therapies with respect to the direct cost of cancer care per patient ($7,272 vs. 
Earlier-Stage Treatment Settings
Kimishima et al. [63] treated 1,088 stage I or II breast cancer patients postoperatively with 5ʹDFUR (an intermediary of capecitabine) with or without cyclophosphamide. Overall, disease-free survival was significantly greater in the 5ʹDFUR/cyclophosphamide group than in the single-agent 5ʹDFUR group (log-rank test, p = .021). The 5ʹDFUR/cyclophosphamide group also had a greater 5-year disease-free survival rate (72% vs. 67%). Grade 3 or 4 AEs did not differ significantly between the treatment groups.
Single-agent capecitabine is being actively investigated for the treatment of breast cancer in the adjuvant setting. The Cancer and Leukemia Group B (CALGB) 49907 study, a randomized, open-label, multicenter, phase III trial that calls for an accrual of 600-1,800 women ≥65 years of age with local or regional breast cancer, is designed to compare the efficacy and safety of single-agent capecitabine with those of standard chemotherapies, CMF or doxorubicin and cyclophosphamide (AC). In the capecitabine arm, patients are administered oral capecitabine at a dose of 1,000 mg/m 2 bid for 2 weeks on/1 week off for 12 weeks, while in the standard chemotherapy arm, patients are administered either: oral cyclophosphamide at a dose of 100 mg/m 2 on days 1-14, parenteral methotrexate at a dose of 40 mg/m 2 on days 1 and 8, and parenteral 5-FU at a dose of 600 mg/m 2 on days 1 and 8 of 4-week cycles or parenteral doxorubicin at a dose of 60 mg/ m 2 on day 1 and cyclophosphamide at a dose of 600 mg/m 2 on day 1 of 3-week cycles for a duration of 12 weeks (Fig. 1) .
Future Directions and Conclusions
Although there are relatively few new trials of singleagent capecitabine for the treatment of breast cancer, capecitabine-based combination therapies are currently under investigation. In the past few years, there have been many publications of capecitabine combined with vinorelbine [64] [65] [66] [67] [68] [69] [70] , taxanes [71] [72] [73] [74] [75] [76] [77] , gemcitabine [78, 79] , bevacizumab [36], erlotinib [80] , and oxaliplatin [81] , as well as ongoing trials: the CALGB 49907 and US Oncology Study 01-062, which is evaluating capecitabine/docetaxel combination therapy versus single-agent docetaxel in the adjuvant setting, and the German AGO group adjuvant study, which is evaluating the role of capecitabine versus no treatment in elderly breast cancer patients [82] . In particular, capecitabine/trastuzumab combination therapy has shown promising efficacy and safety results for first-or secondline therapy in patients with HER2 overexpressing metastatic breast cancer [83, 84] . Single-agent capecitabine has been shown to be an effective, safe, cost-effective agent that provides superior QoL for previously treated patients with metastatic breast cancer. Encouraging results have led to trials in first-line settings that have yielded promising efficacy and safety findings. Favorable findings in elderly patients with metastatic disease have, in turn, led to ongoing trials to assess the efficacy and safety of single-agent capecitabine for elderly patients in the adjuvant setting. Capecitabine continues to develop as an important chemotherapeutic agent for the treatment of breast cancer.
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